+2.97%
Today
Loading 1D prices…
Company profile
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
King of Prussia, PA, United States
Employees
6
Fiscal year end
1231
CIK
1533040
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BLRXBioLineRx Ltd. American Depositary Shares | $12.2M | $1.2M | -99.58% | $0.00 | -2.33% | Buy |
| KPRXKiora Pharmaceuticals Inc. Common Stock | $11.7M | $0.00 | — | -$2.64 | +2.71% | Buy |
| IMRNImmuron Limited American Depositary Shares | $11.7M | — | — | -$0.516 | -11.04% | Unrated |
| TOVXTheriva Biologics Inc. Common Stock | $11.4M | $0.00 | — | -$2.08 | +4.17% | Buy |
| ASBPAspire Biopharma Holdings Inc. Common Stock | $12.7M | $6.2K | -394725.06% | -$16.38 | -0.66% | Unrated |